ReportWire

Tag: DGX

  • Quest Diagnostics Incorporated (NYSE:DGX) Given Average Rating of “Moderate Buy” by Analysts

    [ad_1]

    Quest Diagnostics Incorporated (NYSE:DGX – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the sixteen brokerages that are covering the stock, Marketbeat Ratings reports. Eight analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $198.2667.

    A number of analysts have commented on DGX shares. Weiss Ratings restated a “buy (b-)” rating on shares of Quest Diagnostics in a research note on Monday, December 29th. Evercore ISI lifted their target price on shares of Quest Diagnostics from $185.00 to $190.00 and gave the stock an “in-line” rating in a research report on Wednesday, October 8th. UBS Group lifted their target price on Quest Diagnostics from $180.00 to $190.00 and gave the stock a “neutral” rating in a research note on Friday, October 17th. Wall Street Zen cut shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a report on Sunday, January 25th. Finally, Barclays upgraded Quest Diagnostics from an “equal weight” rating to an “overweight” rating and set a $210.00 price objective on the stock in a research note on Friday.

    View Our Latest Stock Report on DGX

    Insider Activity

    In other news, SVP Mark E. Delaney sold 7,946 shares of the stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $187.35, for a total value of $1,488,683.10. Following the sale, the senior vice president directly owned 7,530 shares of the company’s stock, valued at approximately $1,410,745.50. This represents a 51.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Vicky B. Gregg sold 1,250 shares of the firm’s stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $191.76, for a total transaction of $239,700.00. Following the completion of the transaction, the director directly owned 17,037 shares of the company’s stock, valued at approximately $3,267,015.12. The trade was a 6.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 64,289 shares of company stock worth $12,318,360 over the last ninety days. Company insiders own 8.16% of the company’s stock.

    Institutional Trading of Quest Diagnostics

    A number of hedge funds have recently made changes to their positions in DGX. Brighton Jones LLC bought a new stake in Quest Diagnostics during the fourth quarter worth about $323,000. Janney Montgomery Scott LLC lifted its position in shares of Quest Diagnostics by 11.8% in the 2nd quarter. Janney Montgomery Scott LLC now owns 20,142 shares of the medical research company’s stock worth $3,618,000 after purchasing an additional 2,132 shares during the period. PFG Investments LLC lifted its holdings in Quest Diagnostics by 4.9% in the second quarter. PFG Investments LLC now owns 1,952 shares of the medical research company’s stock worth $351,000 after buying an additional 92 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Quest Diagnostics by 5.7% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,407 shares of the medical research company’s stock valued at $2,768,000 after purchasing an additional 830 shares during the period. Finally, Ameritas Advisory Services LLC purchased a new position in Quest Diagnostics during the second quarter valued at $35,000. 88.06% of the stock is owned by institutional investors.

    Quest Diagnostics Stock Performance

    Shares of Quest Diagnostics stock opened at $186.90 on Monday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.13 and a quick ratio of 1.04. Quest Diagnostics has a one year low of $157.20 and a one year high of $197.55. The business has a 50-day simple moving average of $181.36 and a 200 day simple moving average of $180.73. The firm has a market capitalization of $20.79 billion, a price-to-earnings ratio of 21.94, a PEG ratio of 2.37 and a beta of 0.66.

    Quest Diagnostics Announces Dividend

    The business also recently disclosed a quarterly dividend, which was paid on Wednesday, January 28th. Investors of record on Tuesday, January 13th were paid a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date was Tuesday, January 13th. Quest Diagnostics’s payout ratio is presently 37.56%.

    Quest Diagnostics Company Profile

    (Get Free Report)

    Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

    Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.

    Featured Stories

    Analyst Recommendations for Quest Diagnostics (NYSE:DGX)



    Receive News & Ratings for Quest Diagnostics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Quest Diagnostics and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • DGX Stock Price | Quest Diagnostics Inc. Stock Quote (U.S.: NYSE) | MarketWatch

    DGX Stock Price | Quest Diagnostics Inc. Stock Quote (U.S.: NYSE) | MarketWatch

    [ad_1]

    Quest Diagnostics Inc.

    Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to patients, clinicians, hospitals, health plans, and employers. The All Other segment consists of risk assessment services, healthcare information technology, diagnostic products, and clinical trials testing businesses. The company was founded in 1967 and is headquartered in Secaucus, NJ.

    [ad_2]

    Source link

  • WHO counted nearly 20 million new COVID cases in latest month as it shifts from weekly reporting schedule

    WHO counted nearly 20 million new COVID cases in latest month as it shifts from weekly reporting schedule

    [ad_1]

    The World Health Organization said nearly 20 million new COVID cases were recorded in the 28 days through Jan. 29, down 78% from the previous 28 days.

    The WHO counted more than 114,000 deaths in the period, up 65% from the previous one.

    The agency is switching to a 28-day interval to smooth out weekly fluctuations in cases and deaths, but it continues to caution that a reduction in testing and delays in reporting in many countries are distorting the numbers.

    “Current trends in reported COVID-19 cases are underestimates of the true number of global infections and reinfections as shown by prevalence surveys,” the WHO said in its weekly epidemiological update. 

    The WHO is now prioritizing four omicron descendent lineages, including XBB.1.5, which is dominant in the U.S., according to data from the Centers for Disease Control and Prevention.

    The other three are BF.7, BQ.1 and BA.2.75, along with their sublineages. These are currently the ones showing a growth-rate advantage in some countries compared with other circulating variants.

    U.S. cases are still declining. The seven-day average of new cases stood at 41,771 on Wednesday, according to a New York Times tracker. That’s down 23% from two weeks ago.

    The daily average for hospitalizations was down 22% at 31,593. The average for deaths was 453, down 6% from two weeks ago, but still an undesirably high number heading into the third year of the pandemic and ahead of President Joe Biden’s plan to end the twin COVID emergencies on May 11.

    Coronavirus update: MarketWatch’s daily roundup has been curating and reporting all the latest developments every weekday since the coronavirus pandemic began

    Other COVID-19 news you should know about:

    • Quest Diagnostics Inc.
    DGX,
    -1.55%
    is the latest healthcare company to report a steep drop in revenue from COVID-related products, in this instance a 74.6% slide in tests in its fourth quarter. Revenue from COVID tests fell to $184 million in the quarter from $722 million a year ago, when the omicron wave was about to crest. But the company still posted better-than-expected earnings, raised its quarterly dividend and added $1 billion to its share-buyback authorization, which has $311 million already available. 

    • Hong Kong will give away air tickets and vouchers to woo tourists back to the international financial hub as it races to catch up with other popular travel destinations in a fierce regional competition, the Associated Press reported. During the pandemic, the city largely aligned itself with mainland China’s zero-COVID strategy and has relaxed its entry rules months later than rival destinations such as Singapore, Japan and Taiwan. Even after it reopened its border with mainland China in January, tourism recovery was sluggish. On Thursday, Chief Executive John Lee launched a tourism campaign, “Hello Hong Kong,” saying the city will offer 500,000 free air tickets to welcome tourists from around the world in what he called “probably the world’s biggest welcome ever.”

    • Washington state Gov. Jay Inslee has tested positive for COVID-19 for the second time, the AP reported separately. Inslee’s office said in a statement Wednesday that he had tested positive and was experiencing very mild symptoms, including a cough. He is consulting with his doctor about whether to receive Paxlovid antiviral treatments, according to the statement. He plans to continue working. Trudi Inslee, his spouse, has tested negative.

    Here’s what the numbers say:

    The global tally of confirmed COVID-19 cases topped 671.1 million on Monday, while the death toll rose above 6.83 million, according to data aggregated by Johns Hopkins University.

    The U.S. leads the world with 102.5 million cases and 1,109,687 fatalities.

    The CDC’s tracker shows that 229.6 million people living in the U.S., equal to 69.2% of the total population, are fully vaccinated, meaning they have had their primary shots.

    So far, just 51.4 million Americans, equal to 15.5% of the overall population, have had the updated COVID booster that targets both the original virus and the omicron variants.

    [ad_2]

    Source link